DexCom Inc. Sets New 1-Year High at $28.48 (DXCM)
DexCom (NASDAQ:DXCM) set a new 52-week high during trading on Wednesday, StockRatingsNetwork.com reports. The stock traded as high as $28.48 and last traded at $27.61, with a volume of 199,016 shares. The stock had previously closed at $27.99.
A number of analysts have recently weighed in on DXCM shares. Analysts at Feltl & Co. raised their price target on shares of DexCom (NASDAQ:DXCM) from $16.50 to $18.25 in a research note to investors on Monday, August 12th. They now have a “sell” rating on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of DexCom (NASDAQ:DXCM) in a research note to investors on Thursday, August 8th. They now have a $27.00 price target on the stock, up previously from $21.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom (NASDAQ:DXCM) from $25.00 to $26.00 in a research note to investors on Thursday, August 8th. They now have a “buy” rating on the stock.
Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. DexCom has a consensus rating of “Hold” and a consensus price target of $19.66.
In other DexCom news, CEO Terrance Gregg sold 9,000 shares of the stock on the open market in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $27.00, for a total value of $243,000.00. Following the completion of the transaction, the chief executive officer now directly owns 212,813 shares in the company. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
DexCom has a 1-year low of $12.03 and a 1-year high of $28.17. The stock has a 50-day moving average of $25.40 and a 200-day moving average of $20.59. The company’s market cap is $1.995 billion.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02. The company had revenue of $35.80 million for the quarter, compared to the consensus estimate of $31.14 million. During the same quarter in the previous year, the company posted ($0.21) earnings per share. The company’s revenue for the quarter was up 53.0% on a year-over-year basis. Analysts expect that DexCom will post $-0.53 EPS for the current fiscal year.
DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.